ImmuCell Corporation Down 2.40% To $6.10 After Earnings

ImmuCell Corporation (ICCC) said after close Monday that it lost $0.08 per share in quarter three 2022.

On the revenue line, the company reported $4.8 million, missing estimates by $604 thousand.

In the same quarter a year ago, the company earned $0.02 per share on revenue of $5.2 million.

The stock is down 2.40% to $6.10 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

InvestorsObserver gives the stock a Bearish Sentiment score at the moment based on recent trading.

ImmuCell Corporation has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 22, putting ImmuCell Corporation in the bottom 25% of stocks. The firm was recently trading at a 52-week low of $5.98 on November 21, 2022 and set a 52-week high on April 25, 2022 at $10.96.

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. The company generates the majority of its revenue from the United States.